3 Monster Stocks to Hold for the Next 10 Years

The article highlights three long-term healthcare winners—Eli Lilly, AbbVie, and Abbott Laboratories—citing strong product portfolios and durable growth drivers. Lilly's Mounjaro and Zepbound generated more than $12 billion in the recent quarter, AbbVie's Skyrizi and Rinvoq now offset Humira's patent erosion, and Abbott benefits from diversification plus new product approvals and the Exact Sciences acquisition. This is investor commentary rather than fresh company news, so the likely market impact is limited.

Analysis

The setup is less about three isolated winners and more about the durability of cash-flow compounding in healthcare versus the market’s tendency to overprice near-term patent scares or launch excitement. LLY remains the cleanest growth/margin story, but the market is already paying for execution, so the second-order debate is whether manufacturing scale and payer pushback can cap the speed of monetization over the next 12-18 months. ABBV is the better “fear-to-normalization” trade: as the Humira overhang fades, the stock should increasingly trade on the reinvestment engine rather than the legacy cliff, which usually supports multiple expansion once quarterly comparisons stop looking messy.

ABT is the most underappreciated of the group because it is effectively a self-help + resilience compounder with less headline risk than the GLP-1 or immunology names. The Exact Sciences angle is strategically important: diagnostics is moving from episodic testing toward longitudinal screening and oncology surveillance, which can re-rate the business from a defensive medtech multiple to a more recurring-data platform multiple over time. The AI imaging and glucose-monitoring franchises also create a cross-selling ecosystem that can deepen hospital and physician workflow stickiness, reducing churn and increasing pricing power.

The contrarian takeaway is that the market may be underestimating how much of LLY and ABBV’s perceived growth is already crowded in, while underestimating how much ABT can reaccelerate through product cadence and M&A integration. The main risk is a sentiment reversal driven by reimbursement scrutiny, trial noise, or any sign that obesity demand is normalizing faster than capacity expansion; those events would likely hit LLY first, then spill into the entire healthcare growth basket over days to weeks. If the sector trades up on multiple expansion instead of earnings revisions, expect the higher-duration names to outperform until the next catalyst window closes.

Key Decisions for Investors

• Long ABT vs short XBI for 3-6 months: expresses preference for diversified, cash-generative healthcare over clinical-risk-heavy biotech; target 8-12% relative outperformance if risk appetite cools.
• Add to LLY only on pullbacks of 8-10% or after a quarter of evidence that supply is still binding demand; upside remains substantial, but entry discipline matters because the stock is vulnerable to multiple compression if growth decelerates even slightly.
• Own ABBV as a 12-18 month mean-reversion/re-rating trade: the cleanest risk/reward is that the market stops discounting Humira faster than expected, supporting a 10-15% total return profile plus dividend carry.
• Initiate a smaller tactical long ABT/short LLY pair for 6-9 months: ABT offers lower expectation risk and more diversified catalysts, while LLY carries the highest perfection premium; this pair works if obesity enthusiasm cools but healthcare stays bid.
• Use call spreads rather than outright longs in LLY around earnings: bullish asymmetry remains, but implied volatility likely overstates near-term upside after each catalyst, making spreads the better risk-adjusted expression.